Glatiramer


Article Author:
Arezou Babaesfahani


Article Editor:
Tushar Bajaj


Editors In Chief:
Kranthi Sitammagari
Mayank Singhal


Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Trevor Nezwek
Radia Jamil
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Hussain Sajjad
Steve Bhimji
Muhammad Hashmi
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beata Beatty
Beenish Sohail
Nazia Sadiq
Hajira Basit
Phillip Hynes


Updated:
5/7/2019 10:25:10 AM

Indications

Glatiramer acetate is an immune modulating medication currently used to treat relapsing-remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS).

Michael Sela, Ruth Arnon, and Dvora Teitelbaum at the Weizmann Institute of Science in Rehovot, Israel originally discovered the drug in the 1960s as they were attempting to produce a synthetic antigen capable of inducing experimental autoimmune encephalomyelitis. Experimental autoimmune encephalomyelitis is the animal model of autoimmune inflammatory CNS disorders used by researchers to advance understanding of such neurological conditions. Surprisingly it was noted that the copolymer they created, Cop-1, actually reduced the incidence of encephalitis and severity of histological lesions. After testing Cop-1 on various species and achieving similar results, clinical evaluation of human subjects began in 1977.[1][2]

In 1995, Johnson et al. performed the first randomized, placebo-controlled trial of 20mg glatiramer acetate daily in the United States. The initial positive results obtained on 50 patients with RRMS led to a Phase III clinical trial expansion encompassing 251 patients with RRMS. During the two years of therapy, those patients receiving glatiramer demonstrated a statistically significant decrease in the mean number of relapses compared to those in the placebo group (1.19 vs. 1.68, p=0.0007). In Canada and Europe, Comi et al. performed MRI evaluations on 239 RRMS patients and looked at the reduction in the number of gadolinium-enhancing lesions over 9 months to assess the efficacy of treatment with glatiramer vs. placebo. A statistically significant reduction in the number of lesions was noted amongst the glatiramer receiving patients over those on placebo (26 vs. 36.7, p=0.003). These results led to the Federal Drug Administration’s clearance of the glatiramer acetate for the treatment of RRMS in 1996.[3]

In 2009, a randomized placebo-controlled trial of 20mg daily glatiramer acetate was performed on 481 patients with CIS by Comi et al. This trial deemed “PreCISE” gave rise to a statistically significant (p=0.0005) result indicating a 45% reduction in the risk of developing complete demyelinating multiple sclerosis in those patients receiving glatiramer acetate. PreCISe also resulted in a 115% prolongation of time from CIS conversion to chronic demyelinating multiple sclerosis. These results prompted same year FDA approval of glatiramer acetate in the treatment of CIS.[4]

Mechanism of Action

Glatiramer acetate is a random sized 40 to 100 amino acid polymer composed of primarily of four amino acids L-alanine, L-lysine, L-glutamic acid, and L-tyrosine in a molar ratio 4.2 to 3.4 to 1.4 to 1.0 respectively. The premise behind its mechanism of action lies in the construct that patients with multiple sclerosis have antibodies that are directed against myelin basic protein (MBP), a component of the myelin sheaths of neurons within the central nervous system.  Glatiramer acetate’s chemical construct allows for it to mimic as MBP and thus a decoy for the antibodies in these patients, thereby resulting in a decrease of the inflammatory response. Otherwise, the inflammatory response allows for the vulnerability of the blood-brain barrier to demyelination and axonal injury.[1]

The postulates from multiple clinical studies are that glatiramer acetate shifts the immune response from a pro-inflammatory state comprised of Th1 T-Cells to regulatory, non-inflammatory Th2 T-Cells. The introduction of the polymer allows it to bind to major histone compatibility (MHC) complex class II molecules on MBP-specific antigen presenting cells, preventing MBP from stimulating these cells. Instead of the usual pro-inflammatory cytokine release such as IL-2 and IL-12, anti-inflammatory cytokines such as IL-1, IL-4, and IL-10 are the cytokines dispersed.[5]

While glatiramer acetate itself cannot penetrate the blood-brain barrier, its ability to induce the peripheral Th2 cells and their subsequent crossing of the blood barrier allows reduction of further inflammation within the CNS. This mechanism of action has been dubbed as “bystander suppression.”

Additionally, in the preclinical levels thus far it has been noted that glatiramer acetate induces a neuroprotective and/or neuro-regenerative effect. The drug increases neurotrophic factors like brain-derived neurotrophic factor (BDNF) which has been discovered to be vital to neuronal and glial cell survival. There is also some evidence suggestive of glatiramer’s ability to induce remyelination and enhance neurogenesis.[5][6]  In a study of T cell lines obtained from glatiramer acetate treated multiple sclerosis patients, reactive T cells were found to secrete BDNF.[7][8]

Administration

Glatiramer acetate is to be administered by subcutaneous injection.

  • Sites approved for injection include arms, abdomen, hips, and thighs
  • Recommended to rotate injection sites to minimize the occurrence of lipoatrophy
  • Do not administer intravenously or intramuscularly
  • Glatiramer acetate comes in two dosing schedules: 20mg per mL per day or 40mg per mL three times per week with doses given at least 48 hours apart
  • Glatiramer acetate 20mg per ml and 40mg per ml are not interchangeable
  • It is recommended to allow the solution to warm to room temperature before administration

Given the positive results in reducing relapse rates with implementation of glatiramer acetate in multiple sclerosis patients, curiosity emerged regarding the effects of using the drug at a higher dosage.  

In 2007 researchers performed a phase II clinical trial comparing high dosage 40mg glatiramer acetate to the standard dosage of 20mg, encompassing 38 RRMS patients over nine months. The efficacy assessment was the number of gadolinium-enhancing lesions on MRI. Results showed increased efficacy in the patients on higher dosage glatiramer acetate 40mg as they demonstrated 2.26 lesions on MRI compared to 3.62 lesions seen on MRI in those patients on a standard dosage of 20mg. Safety profiles were comparable amongst the two groups.

The results prompted a phase III, randomized, double-blind, parallel-group trial that embodied over 1155 patients in over 136 sites across 20 different countries to compare daily administration of subQ 40mg versus 20mg glatiramer acetate in one year. Primary outcome efficacy was assessed by the relapse rate in the first year while secondary outcome efficacy was deemed by MRI findings. At the end of one year, no statistically significant difference was found between the two groups; The standard 20mg group had 0.28 mean relapse rate and the higher dosed 40mg group had a 0.27 mean relapse rate. Additionally, the mean number of new T2 lesions and percentage brain volume changes were similar amongst the two groups.[9]

In 2013, Khan et al. performed a phase III, randomized, double-blind study trial including over 1404 patients with RRMS in over 142 sites in 17 countries to compare high dose 40mg glatiramer acetate three times per week to placebo in one year. This study revealed a 34% reduction in risk of confirmed relapses in those receiving treatment compared to those receiving placebo, 0.331 vs. 0.501, p=0.0001.[10] The cumulative number of gadolinium-enhancing lesions were also statistically significantly less than placebo, p less than 0.0001. Thus in 2014, glatiramer acetate 40mg/ml three times a week was approved for RRMS by the FDA.

Adverse Effects

The number one reported side-effect of glatiramer acetate is injection site reaction which manifests as a lump at the site of the subcutaneous injection. Approximately 10% of patients will report fever, chills, and aches. Many patients note a transient episode of flushing, shortness in breath, and palpitations which self resolves within 30 minutes.

Less than 1% of patients will develop lipoatrophy, a visible dent at the injection site due to local necrosis of adipose tissue.  

Serious but rare side effects to various organ systems including cardiovascular, gastrointestinal, hematopoietic, lymphatic, musculoskeletal, nervous, and urogenital systems have been noted, as has Jessner lymphocytic infiltrate, a cutaneous condition characterized by a persistent papule or plaque eruption. 

Contraindications

  • Known hypersensitivity to glatiramer acetate or mannitol
  • Not approved for use for patients less than 18 years of age
  • Pregnancy Category B
  • Not known if nursing mothers excrete glatiramer acetate in human breast milk

Monitoring

A critical issue emerging regarding the use of immunomodulating drugs like glatiramer is the generation of antibodies to the drugs themselves. While conflicting results ensue, a sera analysis study consisting of 217 patients who participated in the treatment and placebo arms of several glatiramer acetate trials were tested for antibodies to glatiramer acetate via ELISA method. IgG antibodies, mainly IgG1, was found in the patients who received active treatment. The titers increased to a peak concentration within 3 months of initiating treatment, but then slowly tapered off. The patients with higher antibody titers seem to be more likely to be relapse free.[6]

Enhancing Healthcare Team Outcomes

Glatiramer acetate is an immunomodulating medication used in the treatment of relapsing-remitting multiple sclerosis as well as a clinically isolated syndrome. The diagnosis of relapsing and remitting multiple sclerosis may be challenging; however, it remains clear there are few medications proven to decrease exacerbations and may even offer neuroprotection. It is essential to consider a multidisciplinary approach with coordination with primary care physicians, neurologists, pharmacists, insurance companies, and other health care professionals to have this medication approved and accessible to patients. Patient education is also crucial with a necessary explanation of how the medication works and the expected clinical treatment course with outcomes.

Glatiramer therapy is best when the administration and follow-up are through a multi-disciplinary healthcare team that includes physicians, specialty-trained nurses, and pharmacists, all working collaboratively to monitor treatment and ensure optimal patient therapeutic outcomes. [Level V]


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Glatiramer - Questions

Take a quiz of the questions on this article.

Take Quiz
A 22-year-old patient presents complaining of transient blurry vision. On neurological exam, there is decreased sensation in her left upper and lower limbs. MRI imaging reveals periventricular lesions including a 2 cm lesion in the right frontal lobe. Lab results further show no oligoclonal bands. She states she has never experienced such symptoms before. Which of the following medications is FDA approved to treat her condition?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 35-year-old female complains of shooting lightning pains down her spine for the last two days. She states she has never experienced such intense pain before. You note pain with extraocular movements on cranial nerve examination. An MRI with and without contrast reveals enhancement of the optic nerve but no other lesions are noted. Which of the following drugs is best started before discharge?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 26-year-old female presents with a history of relapsing-remitting multiple sclerosis. It is decided to add glatiramer acetate into her medical management. How does glatiramer acetate alter her immunological response?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Patients with multiple sclerosis patients have antibodies against myelin basic protein antigens. Glatiramer acetate is composed of 4 amino acids that are found in myelin basic protein. By mimicking the structure of myelin basic protein, the polymer can alter the immunological cascade that ensues in multiple sclerosis due to their antibodies. By what mechanism of action is the immunological cascade altered?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 26-year-old female with newly diagnosed relapsing-remitting multiple sclerosis presents to the clinic regarding treatment options. She recently married and would like to start a family with her husband in the coming months. Which of the following FDA approved drugs for the treatment of multiple sclerosis is considered safest to use in a pregnant patient?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Glatiramer - References

References

Weinstock-Guttman B,Nair KV,Glajch JL,Ganguly TC,Kantor D, Two decades of glatiramer acetate: From initial discovery to the current development of generics. Journal of the neurological sciences. 2017 May 15;     [PubMed]
McKeage K, Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review. CNS drugs. 2015 May;     [PubMed]
Tselis A,Khan O,Lisak RP, Glatiramer acetate in the treatment of multiple sclerosis. Neuropsychiatric disease and treatment. 2007 Apr;     [PubMed]
Caporro M,Disanto G,Gobbi C,Zecca C, Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment. Patient preference and adherence. 2014;     [PubMed]
Khan O,Shen Y,Caon C,Bao F,Ching W,Reznar M,Buccheister A,Hu J,Latif Z,Tselis A,Lisak R, Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2005 Dec;     [PubMed]
Brenner T,Arnon R,Sela M,Abramsky O,Meiner Z,Riven-Kreitman R,Tarcik N,Teitelbaum D, Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. Journal of neuroimmunology. 2001 Apr 2;     [PubMed]
Kerschensteiner M,Gallmeier E,Behrens L,Leal VV,Misgeld T,Klinkert WE,Kolbeck R,Hoppe E,Oropeza-Wekerle RL,Bartke I,Stadelmann C,Lassmann H,Wekerle H,Hohlfeld R, Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? The Journal of experimental medicine. 1999 Mar 1;     [PubMed]
Chen M,Gran B,Costello K,Johnson K,Martin R,Dhib-Jalbut S, Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Multiple sclerosis (Houndmills, Basingstoke, England). 2001 Aug;     [PubMed]
Comi G,Martinelli V,Rodegher M,Moiola L,Bajenaru O,Carra A,Elovaara I,Fazekas F,Hartung HP,Hillert J,King J,Komoly S,Lubetzki C,Montalban X,Myhr KM,Ravnborg M,Rieckmann P,Wynn D,Young C,Filippi M, Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2009 Oct 31;     [PubMed]
Khan O,Rieckmann P,Boyko A,Selmaj K,Zivadinov R, Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Annals of neurology. 2013 Jun;     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of PA-Hospital Medicine. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for PA-Hospital Medicine, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in PA-Hospital Medicine, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of PA-Hospital Medicine. When it is time for the PA-Hospital Medicine board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study PA-Hospital Medicine.